VolitionRx (NYSE-A:VNRX), the multinational epigenetics company, said it was “delighted” to host Ambassador Michael Adler, the US Ambassador to the Kingdom of Belgium, for an exclusive tour of its state-of-the-art research, development, and manufacturing facilities located in Isnes, Belgium.
"Ambassador Adler's visit today was an ideal opportunity for us to celebrate this collaborative work and highlight the close ties we have fostered between US and Belgian stakeholders over the last 13 years,” Gaetan Michel, Volition’s COO said in a statement.
“Cultivating successful, ongoing relationships with stakeholders worldwide has been fundamental to Volition's development."
Volition is at the forefront of developing accessible, cost-effective blood tests designed to aid in the diagnosis and monitoring of various life-altering diseases, including specific cancers and diseases associated with NETosis such as sepsis.
Volition boasts purpose-built research and development centers in Belgium, complemented by a cutting-edge innovation lab in California.
“As a company, we benefit enormously from this talent pool, joint working, and shared experience and it has undoubtedly accelerated our growth,” COO Michel added.
Gaetan Michel, Chief Operating Officer at Volition, expressed delight in welcoming Ambassador Adler and introducing him to the expert team, showcasing the company's groundbreaking epigenetic technology, and emphasizing its potential to significantly enhance patient outcomes on a global scale.
Volition's current product lineup includes the Nu.Q Cancer Vet Test, a diagnostic tool for early cancer detection and monitoring in dogs, and Nu.Q NETs, a CE Marked test for detecting diseases associated with NETosis.